Cytosorbents Advances DrugSorb™-ATR Regulatory Strategy with New De Novo Application Submission

Cytosorbents Advances Regulatory Strategy for DrugSorb™-ATR Device

Cytosorbents Corporation continues to make significant strides in the development of its innovative DrugSorb™-ATR device. On September 16, 2025, the company announces a critical regulatory update following an FDA appeal decision from August 20, which confirmed that the device poses no safety concerns. However, the FDA maintains its denial of the De Novo application, requiring additional supporting information for the desired label indication. In a proactive response, Cytosorbents engages in discussions with FDA officials and determines not to pursue a further appeal but instead to focus on submitting a new De Novo application.

This new application promises to incorporate vital real-world data, particularly from patients treated with ticagrelor during urgent coronary artery bypass graft surgery. The inclusion of this data is crucial as it was not available in the initial submission and is expected to enhance the understanding of the device's clinical efficacy and safety profile. By taking this approach, Cytosorbents aims to strengthen its case for market authorization and clarify any outstanding issues identified in the first review. The company expresses confidence that the FDA will prioritize the review process under the Breakthrough Device Designation, which allows for expedited evaluation and interactive dialogue.

Cytosorbents’ decision to pursue an updated application reflects its commitment to advancing cutting-edge blood purification solutions in critical care environments. This strategy not only aligns with regulatory expectations but also underscores the company's dedication to improving patient outcomes through innovative medical technology. As the company prepares to submit its application, it remains focused on addressing the FDA's concerns and demonstrating the DrugSorb™-ATR device's potential impact in healthcare settings.

In addition to its regulatory endeavors, Cytosorbents catches the attention of analysts who provide a spectrum of ratings and insights into the company's performance and outlook. This diverse range of opinions highlights the dynamic nature of the market in which Cytosorbents operates, influenced by ongoing clinical trials and competitive pressures. The analysts' perspectives are invaluable for stakeholders as they navigate the complexities surrounding the company's future prospects.

As Cytosorbents moves forward with its strategic initiatives, the emphasis on regulatory compliance and real-world evidence will be crucial in establishing the DrugSorb™-ATR device as a viable solution in the healthcare market. The proactive approach taken by the company signals its resilience and commitment to innovation, essential in a rapidly evolving medical landscape.